Semaglutide weight loss timeline: what to expect month by month
Semaglutide doesn't work overnight, and the trial data shows a predictable curve. Here's a realistic month-by-month picture built from the STEP 1 and STEP 5 randomized trials, not marketing promises.
The month-by-month curve
Weight loss on semaglutide follows an S-curve: slow in the first few weeks during titration, steep through the middle of the year, then flattening as you approach your effective dose. In STEP 1, the average participant reached roughly 5% loss by week 12, about 10% by week 28, and the full ~14.9% by week 68.
The first four weeks are the 0.25 mg starter dose, which is deliberately sub-therapeutic — it exists to reduce nausea, not to drive loss. Real appetite suppression typically becomes noticeable at 1.0 mg and above.
One practical note: weigh yourself at the same time and under the same conditions, and average across a week. Daily weight swings of two to four pounds from water and food are normal and can mask the real downward trend that the trial curves describe.
Why the plateau happens — and what it means
A plateau is not failure. As you lose weight, your body burns fewer calories at rest, and the dose that drove early loss reaches a new equilibrium. In STEP 5, the two-year trial, mean loss was about 15.2% — only marginally more than the 68-week figure, confirming most loss happens in year one.
If you plateau below your goal, options include confirming you're at the 2.4 mg maintenance dose, tightening nutrition and resistance training, or discussing a switch to tirzepatide, which produced larger average loss in head-to-head data.
It also helps to reframe the goal. The health benefits of GLP-1 therapy — improved blood pressure, glucose, and cardiovascular risk — accrue at your reduced weight even when the scale stops moving, so a plateau still delivers value while you work on the next step.
| Milestone | Typical timing | Approx. loss |
|---|---|---|
| First appetite change | Weeks 4–8 | 2–4% |
| Noticeable clothing change | Weeks 12–20 | 5–8% |
| Strongest phase | Weeks 20–40 | 10–13% |
| Plateau / maintenance | Weeks 52–68 | ~15% |
What makes some people lose more
The single strongest predictor in the trials was early response: patients who lost ≥5% by week 12 were far more likely to reach ≥15% by the end. Adherence to the weekly injection, reaching the full 2.4 mg dose, and pairing the drug with protein-forward nutrition and resistance training all move the number.
Cost and continuity matter too — the people who get trial-like results are the ones who stay on treatment long enough to reach and hold the maintenance dose, which is why a predictable monthly price is part of the outcome equation.
The right answer here is genuinely individual. Your medical history, current medications, budget, and goals all shape the best path, which is why this is educational context to bring to a clinician rather than a one-size prescription.
The bottom line
Set realistic expectations: a healthy target is 12–15% over the first year, with the fastest change between months two and eight. Track trends over weeks, not daily fluctuations, and judge progress by how your clothes fit and your labs move, not the scale alone.
If your curve is flatter than the trial average, don't panic — response varies with dose, adherence, sleep, and baseline metabolism. The more useful question than 'am I losing fast enough?' is 'am I still trending down and building habits I can keep?'
The consistent lesson from the evidence is that semaglutide rewards persistence and support. Weight and metabolic benefits track with reaching an effective dose and holding it, paired with protein and strength training; they fade when treatment stops. So when comparing options, weigh not just the headline price but whether the program's cost and clinical support let you stay the course.
How we verify pricing & evidence
The prices here come from the RangeYourself independent telehealth price index, human-verified against each provider's public pricing page during July 1–3, 2026 (CC-BY-4.0, attributed). Efficacy and safety figures are drawn from the STEP (semaglutide) and SURMOUNT (tirzepatide) pivotal-trial programs and peer-reviewed outcome studies. Prices change, so confirm the current rate at your dose before deciding — and note that compounded GLP-1s are not FDA-approved and aren't identical to the brand drugs studied in those trials.
Frequently asked questions
Appetite suppression often starts within the first month, but meaningful weight loss (5%+) typically takes about 12 weeks. The steepest loss occurs between months 2 and 8 in trial data.
Most people plateau around months 12–14. In the two-year STEP 5 trial, average loss was ~15.2%, only slightly above the 68-week figure, so year one drives most of the result.
Confirm you've reached the 2.4 mg maintenance dose. Losing less than 5% by week 12 predicts a weaker response; discuss dose, nutrition, or a switch to tirzepatide with your clinician.
Often, yes. The STEP 1 extension found about two-thirds of lost weight returned within a year of stopping, so semaglutide is generally a long-term therapy.
Key takeaways
- Expect ~5% loss by week 12, ~10% by week 28, and ~15% by week 68 on the 2.4 mg dose, mirroring STEP 1.
- The steepest loss happens between months two and eight; the first month is mostly tolerance-building at sub-therapeutic doses.
- Losing at least 5% by week 12 is the strongest predictor of reaching 15%+ long-term.
- Plateaus near month 12–14 are expected and largely reflect year-one capturing most of the loss.